Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?

BACKGROUND: Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, a major concern is the significant adverse effects associated with long term-us...

Descripción completa

Detalles Bibliográficos
Autores principales: Kourakis, Stephanie, Timpani, Cara A., Campelj, Dean G., Hafner, Patricia, Gueven, Nuri, Fischer, Dirk, Rybalka, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934375/
https://www.ncbi.nlm.nih.gov/pubmed/33663533
http://dx.doi.org/10.1186/s13023-021-01758-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934375/
https://www.ncbi.nlm.nih.gov/pubmed/33663533
http://dx.doi.org/10.1186/s13023-021-01758-9

Ejemplares similares